Literature DB >> 2765186

Nucleus accumbens cholecystokinin (CCK) can either attenuate or potentiate amphetamine-induced locomotor activity: evidence for rostral-caudal differences in accumbens CCK function.

F J Vaccarino1, J Rankin.   

Abstract

In this study the effects of cholecystokinin (CCK) microinjections into the rostral or caudal nucleus accumbens (Acc) on locomotor activation derived from systemic amphetamine treatment were examined. It was found that CCK microinjections into the rostral Acc attenuated and CCK microinjections into the caudal Acc potentiated amphetamine-induced locomotor activity. Results indicate that rostral Acc CCK microinjections have dopamine antagonistlike effects and caudal Acc CCK microinjections have dopamine agonistlike effects on amphetamine-induced locomotor activity. The relevance of the present findings to previous results regarding CCK-dopamine interactions is discussed.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2765186

Source DB:  PubMed          Journal:  Behav Neurosci        ISSN: 0735-7044            Impact factor:   1.912


  12 in total

1.  Opposing Roles of Rapid Dopamine Signaling Across the Rostral-Caudal Axis of the Nucleus Accumbens Shell in Drug-Induced Negative Affect.

Authors:  Seth W Hurley; Elizabeth A West; Regina M Carelli
Journal:  Biol Psychiatry       Date:  2017-05-11       Impact factor: 13.382

2.  Anatomical differentiation within the nucleus accumbens of the locomotor stimulatory actions of selective dopamine agonists and d-amphetamine.

Authors:  W D Essman; P McGonigle; I Lucki
Journal:  Psychopharmacology (Berl)       Date:  1993       Impact factor: 4.530

3.  Devazepide, a CCKA receptor antagonist, impairs the acquisition of conditioned reward and conditioned activity.

Authors:  S A Josselyn; V P Franco; F J Vaccarino
Journal:  Psychopharmacology (Berl)       Date:  1996-01       Impact factor: 4.530

4.  Cholecystokinin and psychiatric disorders : role in aetiology and potential of receptor antagonists in therapy.

Authors:  J Shlik; E Vasar; J Bradwejn
Journal:  CNS Drugs       Date:  1997-08       Impact factor: 5.749

5.  Cholecystokinin activates CCKB receptors to excite cells and depress EPSCs in the rat rostral nucleus accumbens in vitro.

Authors:  Samuel B Kombian; Kethireddy V V Ananthalakshmi; Subramanian S Parvathy; Wandikayi C Matowe
Journal:  J Physiol       Date:  2003-12-12       Impact factor: 5.182

6.  Facilitation and inhibition of feeding by a single dose of amphetamine: relationship to baseline intake and accumbens cholecystokinin.

Authors:  T L Sills; F J Vaccarino
Journal:  Psychopharmacology (Berl)       Date:  1991       Impact factor: 4.530

Review 7.  Cholecystokinin receptor subtypes: role in the modulation of anxiety-related and reward-related behaviours in animal models.

Authors:  Susan Rotzinger; Franco J Vaccarino
Journal:  J Psychiatry Neurosci       Date:  2003-05       Impact factor: 6.186

8.  Role of N-methyl-D-aspartic acid and cholecystokinin receptors in apomorphine-induced aggressive behaviour in rats.

Authors:  A Lang; J Harro; A Soosaar; S Kõks; V Volke; L Oreland; M Bourin; E Vasar; J Bradwejn; P T Männistö
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1995-04       Impact factor: 3.000

9.  The stimulation of cholecystokinin receptors in the rostral nucleus accumbens significantly antagonizes the EEG and behavioural effects induced by phencyclidine in rats.

Authors:  P Popoli; R Reggio; A Pèzzola; A Scotti de Carolis
Journal:  Psychopharmacology (Berl)       Date:  1995-07       Impact factor: 4.530

10.  Analysis of neuropeptide expression and localization in adult drosophila melanogaster central nervous system by affinity cell-capture mass spectrometry.

Authors:  Joanne Y Yew; Yun Wang; Natasha Barteneva; Sergei Dikler; Kimberly K Kutz-Naber; Lingjun Li; Edward A Kravitz
Journal:  J Proteome Res       Date:  2009-03       Impact factor: 4.466

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.